Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2003 Jan-Feb;18(1):54-8.
doi: 10.1159/000066386.

Cervical ripening with prostaglandin E1: how an ambulatory method decreases the hospital stay in abortus with intrauterine fetal demise

Affiliations
Clinical Trial

Cervical ripening with prostaglandin E1: how an ambulatory method decreases the hospital stay in abortus with intrauterine fetal demise

Marcelino Hernandez-Valencia. Fetal Diagn Ther. 2003 Jan-Feb.

Abstract

Objective: This study was designed to determine whether use of prostaglandin E(1 )(PGE(1)) is justified to improve the known clinical outcome of prostaglandin E(2) (PGE(2)) gel, because PGE(2) gel preparations are more costly than PGE(1) tablets in most countries, and data to support the use of the gel in clinical practice is not conclusive. The aim was to compare the safety and efficacy of PGE(1) gel when applied in both an in-hospital or ambulatory setting to oxytocin infusion in those women with unfavorable cervical conditions prior to surgical abortion for either medical or obstetrical indications with intrauterine fetal demise. Surgical dilatation of the unripe cervix may result in cervical injury of uterine perforation which could prolong the hospital stay.

Methods: We used PGE(1) gel prepared from tablets and administered in the ambulatory form (group 1), the same PGE(1) gel administered in the labor room (group 2) and intravenously administered oxytocin in the labor room (group 3) for the induction of abortus in women complicated with intrauterine fetus death and missed abortion. Patients requesting abortion were eligible for inclusion, with >8 and <13 weeks of gestation. Eighty-nine women with unfavorable cervices (Bishop score </=4) were included in this study. Comparisons between the three groups for such variables were done by ANOVA.

Results: The statistical test did reveal significant differences in the cervical changes, doses of PGE(1) used and maternal labor stay between the three groups. The difference in effect on cervical ripening was seen following PGE(1) application in both of these groups, but no difference was seen with the oxytocin use. Cervical score changed in 100% of both groups with the PGE(1) gel and 89.6% of the group with oxytocin use, within 6 days in the latter group. The mean number of days of maternal labor stay were 1.5, 4.6 and 6.2 respectively. There was no difference regarding the effect on clinical characteristics of the women on the final Bishop score. The number, initial and final Bishop score, vaginal bleeding and other complications were not different.

Conclusions: Duration of hospital stay may be decreased by applying PGE(1) gel in an ambulatory setting when compared to in-hospital PGE(1) gel applications or intravenous oxytocin infusion for cervical ripening. Further research is necessary to determine the safety of PGE(1) gel application for preabortion cervical ripening prior to surgical abortion.

PubMed Disclaimer

LinkOut - more resources